Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dimethyl fumarate Clear all
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

NCT03870763
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Biogen Multiple Sclerosis Pregnancy Exposure Registry

NCT01911767
View directory record Official record
Conditions
Multiple Sclerosis, Exposure During Pregnancy
Interventions
Dimethyl fumarate, Peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Dimethyl Fumarate (DMF) Observational Study

NCT02047097
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
5,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 140 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Tecfidera Lymphocyte Chart Review

NCT02519413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Homewood, Alabama • Newport Beach, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 22, 2026, 12:31 AM EDT
Terminated Phase 3 Interventional Results available

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

NCT02430532
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive
Interventions
dimethyl fumarate, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Long Beach, California • San Francisco, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
38
States / cities
Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

NCT03284970
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 22, 2026, 12:31 AM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 22, 2026, 12:31 AM EDT
Terminated Phase 1 Interventional Results available

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

NCT02784834
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
dimethyl fumarate
Drug
Lead sponsor
Michael Choi
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 22, 2026, 12:31 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 22, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

NCT02171208
View directory record Official record
Conditions
Healthy
Interventions
dimethyl fumarate - Reference form, dimethyl fumarate - Test form
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Sep 22, 2026, 12:31 AM EDT
Terminated Phase 1 Interventional Results available

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

NCT02981082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary; Hypertension
Interventions
Dimethyl Fumarate (DMF), Placebo Oral Tablet
Drug
Lead sponsor
Robert Lafyatis
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 22, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Study Drug, Active Control, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

NCT05576779
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ofatunumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 22, 2026, 12:31 AM EDT
Not listed No phase listed Observational

Impact of Tecfidera on Gut Microbiota

NCT02736279
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dimethyl fumarate
Drug
Lead sponsor
Virginia Simnad
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 22, 2026, 12:31 AM EDT
Active, not recruiting Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Dimethyl Fumarate for Obstructive Sleep Apnea

NCT02438137
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions
Dimethyl fumarate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Teriflunomide Tecfidera LMCE

NCT03526224
View directory record Official record
Conditions
Tecfidera, Teriflunomide
Interventions
Dimethyl Fumarate, Teriflunomide
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 22, 2026, 12:31 AM EDT
Active, not recruiting No phase listed Observational

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

NCT07757568
View directory record Official record
Conditions
Multiple Sclerosis (MS) Relapsing Remitting
Interventions
Vumerity, Tecfidera
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 22, 2026, 12:31 AM EDT
Terminated No phase listed Observational

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

NCT02218879
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tecfidera
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 22, 2026, 12:31 AM EDT
Withdrawn Phase 4 Interventional

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

NCT02675413
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 22, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT02555215
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 22, 2026, 12:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

NCT02683863
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00012 (DMF) (Tecfidera®.)
Drug
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 22, 2026, 12:31 AM EDT
Completed No phase listed Observational

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

NCT02159573
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, dimethyl fumarate
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Sep 22, 2026, 12:31 AM EDT